Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Meribank Biotech CoROCO:4724 -3.65%40 PB Ratio is 0.75 as of Jul. 19, 2026, which is 70% below its 10-year median of 2.49. GuruFocus rates ROCO:4724 with a GF Score™ of 40/100 and a GF Value™ of NT$48.92 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,232 Biotechnology companies, Meribank Biotech Co ranks better than 88.15% on this metric.
Meribank Biotech Co Ltd stock PB Ratio (=0.75) is close to 5-year low of 0.73.
The historical rank and industry rank for Meribank Biotech Co's PB Ratio or its related term are showing as below:
ROCO:4724'
s PB Ratio Range Over the Past 10 Years
Min: 0.73 Med: 2.49 Max: 6.53
Current: 0.75
During the past 8 years, Meribank Biotech Co's highest PB Ratio was 6.53. The lowest was 0.73. And the median was 2.49.
ROCO:4724's PB Ratio is ranked better than 88.15% of 1232
companies
in the Biotechnology industry
Industry Median: 2.825
vs ROCO:4724: 0.75
During the past 12 months, Meribank Biotech Co's average Book Value Per Share Growth Rate was -5.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 20.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 16.10% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Meribank Biotech Co was 20.50% per year. The lowest was 2.80% per year. And the median was 14.00% per year.
Back to Basics: PB Ratio
Meribank Biotech Co (ROCO:4724) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Meribank Biotech Co PB Ratio Related Terms
Meribank Biotech Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Meribank Biotech Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4724 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Meribank Biotech Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meribank Biotech Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Meribank Biotech Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Meribank Biotech Co (ROCO:4724) has a PB Ratio of 0.75 as of Jul. 19, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Meribank Biotech Co and its competitors. This is 70% below median its historical median of 2.49. Over the past decade, Meribank Biotech Co's PB Ratio has ranged from 0.73 to 6.53. According to the industry distribution chart, Meribank Biotech Co ranks #146 out of 1232 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Meribank Biotech Co's PB Ratio too high?
Meribank Biotech Co's current PB Ratio of 0.75 is 70% below median its 10-year median of 2.49. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 6.53. The Biotechnology industry median PB Ratio is 2.83. Meribank Biotech Co's value of 0.75 is 73.5% below this industry median. Based on the distribution chart, Meribank Biotech Co ranks #146 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Meribank Biotech Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Meribank Biotech Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Meribank Biotech Co ranks #146 out of 1232 companies for PB Ratio. This places Meribank Biotech Co in the top 12% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.83. Meribank Biotech Co's value of 0.75 is 73.5% below this benchmark. Historically, Meribank Biotech Co's own PB Ratio has ranged from 0.73 to 6.53 over the past decade. While the company's 10-year median is 2.49 vs. the industry median of 2.83, Meribank Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Meribank Biotech Co's current PB Ratio of 0.75 is 73.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Meribank Biotech Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Meribank Biotech Co's current PB Ratio is 0.75, which is 70% below median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meribank Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Meribank Biotech Co (ROCO:4724) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.92, compared to a current price of NT$9.78 — trading 80% below its estimated fair value. The current PB Ratio is 0.75, which is 70% below median its 10-year median of 2.49 and 73.5% below the Biotechnology industry median of 2.83. Meribank Biotech Co's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Meribank Biotech Co (ROCO:4724), the current PB Ratio is 0.75 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Meribank Biotech Co (ROCO:4724) Overvalued in 2026?
Based on GuruFocus' analysis, Meribank Biotech Co stock appears to be undervalued.
The current stock price of NT$9.78 is trading 80% below its estimated GF Value™ of NT$48.92.
GuruFocus considers Meribank Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:4724:
PB Ratio: 0.75 (70% below median its 10-year median of 2.49)
GF Value™: NT$48.92 vs. price of NT$9.78 (80% below fair value)
Industry Position: 73.5% below the Biotechnology median (#146 of 1232)
No single metric tells the full story. See the ROCO:4724 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.
40GF Score
Get the complete analysis for ROCO:4724
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4724 has been successfully added to your 
